This page has been archived on the Web
Information identified as archived is provided for reference, research or recordkeeping purposes. It is not subject to the Government of Canada Web Standards and has not been altered or updated since it was archived. Please contact us to request a format other than those available.
MAR-Paliperidone Extended Release Tablets: Data Integrity
Summary
See instructions below.
Affected products
Brand |
Product Name |
Market Authorization |
Dosage Form |
Strength |
Lot |
|---|---|---|---|---|---|
MAR-Paliperidone |
MAR-Paliperidone 3mg |
DIN 02511010 |
Tablet (Extended-Release) |
Paliperidone 3 mg |
M210315 |
MAR-Paliperidone |
MAR-Paliperidone 6mg |
DIN 02511029 |
Tablet (Extended-Release) |
Paliperidone 6mg |
M210316 |
Issue
Data integrity concerns with product's bioequivalence data.
What you should do
- Verify if your product is affected.
- Consult your healthcare provider prior to discontinuing use of the affected product(s), or for any health concerns.
- Contact the recalling firm if you have any questions about the recall.
- Report any health product related side effects to Health Canada.
- Report any other health product safety complaints to Health Canada.
Additional information
Background
Depth of Recall: Retailers
Details
|
Marcan Pharmaceuticals Inc. 2 Gurdwara Road, Suite #112, Ottawa, Ontario, K2E 1A2 |
Get notified
Receive emails about new and updated recall and safety alerts.